ONCOCheck – Myeloid Leukemia
ONCOCheck Myeloid Leukemia uses next generation sequencing (NGS) technology to targets mutations in 54 genes (tumor suppressor genes and oncogenic hotspots) involved in different onco-hematological disease: acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML).
The result is a single genetic test for accurate, economical, and rapid profiling of hematological tumors.
- Time-Efficient Solution
- The test targets 15 full genes (exons only) plus exonic hotspots of an additional 39 genes, providing nearly 100% coverage of all targeted regions
- High-Accuracy, High-Sensitivity Analysis: limit of detection down to 5% mutant allele frequency
TECHNOLOGY USED: NGS – Next Generation Sequencing
BIOLOGICAL SAMPLE: blood, bone marrow
REQUIRED DOCUMENTS: physician requesting form and the informed consent to perform the genetic test signed by the patient.
For further information about collection and shipment of samples, and to receive analysis application forms or other clarifications contact us.